



Ms. Erica Lessem

Global TB Community Advisory Board

Treatment Action Group

June 23, 2015

Dear Erica,

Thank you for bringing your concerns about the development of sutezolid to our attention. The license of the sutezolid patent rights provides a means to ameliorate this situation. Johns Hopkins University appreciates and has acted upon the Treatment Action Group's requests.

Regarding the rapid development of sutezolid, we have strengthened our license provisions to include specific dates for meeting development milestones and intend to hold Sequella to that timeline.

As to ensuring access provisions for collaborative research, we have engaged with Medicine's Patent Pool to understand the structure of their agreements for use in a sutezolid patent license. Additionally, we solicited comments from the TB community, and sought to incorporate them in our draft agreement.

Finally, we sought the perspective and feedback of TB-affected communities to the terms of the agreement. Representative members of the TB Association, Doctors without Borders, UAEM and the Gates Foundation have provided specific comments upon our request. This was done in conjunction with Johns Hopkins TB clinician Susan Dorman, MD, a professor and leading expert in drug resistant TB with extensive patient and clinical trial experience, as well as Thomas Quinn, MD, who runs the Johns Hopkins Center for Global Health. These comments and suggestions to the license have helped aid in the drafting of a strong agreement for the parties involved.

The university is committed to diligence milestones that obligate our licensee to achieve development and access goals in a reasonable time. Failure to achieve these milestones would require the university, as licensor, to exercise its license rights regarding breach and termination. Likewise, Sequella, with the financial backing of Celgene, is also fully committed to moving sutezolid along the development timeline as quickly as is reasonably possible. Along those lines, it is equally important that Sequella complete the testing necessary to ensure that sutezolid is safe and effective for use as part of a combination therapy for TB before allowing the broad administration of sutezolid to humans.

Thanks again for reaching out to us. I hope that our answers have given you some assurance that sutezolid will be developed in line with our mutual goal: in the safest and fastest way possible so that we can begin treating patients.

Sincerely,

A handwritten signature in blue ink that reads "Neil Veloso".

Neil Veloso, Executive Director, Technology Transfer